维生素D缺乏增加个体对卡格列净所致1,25-二羟维生素D和甲状旁腺激素不良反应的易感性
该社区门诊配对设计研究纳入11例维生素D缺乏(25(OH)D≤20 ng/mL)的Amish个体,比较维生素D3补充前后卡格列净(300 mg每日5天)挑战试验中1,25(OH)2D和PTH的变化。结果显示维生素D3补充使卡格列净引起的1,25(OH)2D降幅从-31.3%±4.7%减小至-9.3%±8.3%(P=.04),PTH升幅从+36.2%±6.2%减小至+9.7%±3.7%(P=.005)。结论认为维生素D缺乏增加个体对卡格列净骨健康相关生物标志物不良反应的易感性,维生素D3补充具有保护作用。
要点
- 维生素D缺乏(25(OH)D≤20 ng/mL)者使用卡格列净后1,25(OH)2D降幅和PTH升幅更大。
- 维生素D3补充使25(OH)D从16.5±1.6升至44.3±5.5 ng/mL(P=.0006)。
- 补充后卡格列净引起的1,25(OH)2D降幅和PTH升幅均减小,差异有统计学意义。
核心结论
- 维生素D缺乏使个体对卡格列净在骨健康相关生物标志物上的不良反应更易感。
- 维生素D3补充对卡格列净短期引起的1,25(OH)2D和PTH不良反应具有保护作用。
研究设计与样本
- 社区门诊配对设计研究,比较同一批受试者维生素D3补充前后的变化。
- 从宾夕法尼亚州兰开斯特Amish人群中招募11例维生素D缺乏(25(OH)D≤20 ng/mL)个体。
- 受试者接受两次卡格列净挑战方案(300 mg每日一次,连续5天):第一次在维生素D3补充前,第二次在补充后。
- 维生素D3补充方案:根据体重指数给予50000 IU每周一次或两次,持续4-6周,以使25(OH)D达到30 ng/mL或以上。
- 共同主要终点为维生素D3补充对卡格列净引起的1,25(OH)2D和PTH变化的影响;次要终点包括维生素D3补充对维生素D代谢物和PTH基线水平的影响。
主要发现
- 维生素D3补充使平均25(OH)D从16.5±1.6升至44.3±5.5 ng/mL(P=.0006)。
- 维生素D3补充使平均24,25-二羟维生素D从1.0±0.1升至4.3±0.6 ng/mL(P=.0002)。
- 平均1,25(OH)2D和PTH基线水平在补充前后无变化。
- 维生素D3补充使卡格列净引起的1,25(OH)2D降幅从-31.3%±4.7%减小至-9.3%±8.3%(P=.04)。
- 维生素D3补充使卡格列净引起的PTH升幅从+36.2%±6.2%减小至+9.7%±3.7%(P=.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Canagliflozin has been reported to increase the risk of bone fracture-possibly mediated by decreasing 1,25-dihydroxyvitamin D (1,25(OH)2D) and increasing parathyroid hormone (PTH). OBJECTIVE: This work investigated whether baseline vitamin D (VitD) deficiency renders individuals vulnerable to this adverse effect and whether VitD3 supplementation is protective. METHODS: This community-based, outpatient study had a paired design comparing individual participants before and after VitD3 supplementation. Eleven VitD-deficient (25-hydroxyvitamin D [25(OH)D] ≤ 20 ng/mL) individuals were recruited from the Amish population in Lancaster, Pennsylvania. Participants underwent 2 canagliflozin challenge protocols (300 mg daily for 5 days): the first before and the second after VitD3 supplementation. In the VitD3 supplementation protocol, participants received VitD3 supplementation (50 000 IU once or twice a week depending on body mass index for 4-6 weeks) to achieve 25(OH)D of 30 ng/mL or greater. Two coprimary end points were identified: effects of VitD3 supplementation on canagliflozin-induced changes in 1,25(OH)2D and PTH. Secondary end points included effects of VitD3 supplementation on baseline levels of VitD metabolites and PTH. RESULTS: VitD3 supplementation increased mean 25(OH)D from 16.5 ± 1.6 to 44.3 ± 5.5 ng/mL (P = .0006) and 24,25-dihydroxyvitamin D (24,25(OH)2D) from 1.0 ± 0.1 to 4.3 ± 0.6 ng/mL (P = .0002). Mean 1,25(OH)2D and PTH were unchanged. VitD3 supplementation decreased the magnitude of canagliflozin-induced changes in 1,25(OH)2D (from -31.3%±4.7% to -9.3%±8.3%; P = .04) and PTH (from +36.2%±6.2% to +9.7%±3.7%; P = .005). CONCLUSION: VitD deficiency rendered individuals more vulnerable to adverse effects of canagliflozin on biomarkers associated with bone health. VitD3 supplementation was protective against canagliflozin's short-term adverse effects on 1,25(OH)2D and PTH.
引用
- Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, et al. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH. J Clin Endocrinol Metab. 2024. PMID: 37738423. doi:10.1210/clinem/dgad554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。